Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReMEDy2: DM199 in Acute Ischemic Stroke
NCT05065216Phase 3Recruiting
- Sponsor
- DiaMedica Therapeutics
- Start
- Nov 2021
- Primary completion
- Dec 2026
- Modality
- Replacement Enzymes
- Countries
- 10
01
Overview
A Phase 3 trial of rinvecalinase alfa in ischemic stroke, sponsored by DiaMedica Therapeutics. Started Nov 2021; status: recruiting.
02
Drugs
rinvecalinase alfa
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05065216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05065216.